Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV:
$KHRN.V) (NASDAQ: $NEPT) (NYSE: $ACB) (TSX: $ALEF.TO) (NASDAQ: $GWPH)
Delta, Kelowna, BC
–November 11, 2019- (Investorideas.com Newswire) Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s podcast
edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
Read this in full
at
Good afternoon and
welcome to another episode of Investorideas.com "Potcast" featuring
cannabis news, stocks to watch as well as insights from thought leaders and
experts
In
today’s podcast we look at a few early announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) announced today that the Company will introduce the
Aceso™ Hemp brand to the Latin America market, with initial sales beginning in
Q4 2019 in Colombia. Aceso Hemp, which is part of the Dixie Brands family of
products, produces a line of innovative balms for the growing hemp-based
consumer wellness market, and is widely established in the US market. Aceso
represents the first brand to enter the Latin America market under the
Company's joint venture with Dixie
Brands Inc. (CSE: DIXI.U).
Aceso
Hemp is the next generation in hemp, pairing plant science with food science.
Offering a growing line of indication-specific, hemp-derived supplements for
promoting optimal health, Aceso Hemp was one of the first entrants in the
category and brings a deep understanding of the industry's complex regulatory
structure and expertise in the production of safe, effective and compliant
products that can be sold across the United States. Aceso Hemp's scientists
have studied, tested and perfected phyto-nutrient ratios that unlock the powers
of hemp, resulting in sophisticated formulas that are easy for the body to
absorb and activate.
With its
market-leading knowledge of the Latin American market Khiron will initially
prioritize two Aceso products for commercialization in the Colombian market.
Aceso Alfa Balm and Aceso Sigma Balm blend essential oils and ingredients to
soothe aching muscles and revitalize skin, and enhance their impact with
broad-based hemp. Each product contains 56 mg of naturally occurring
cannabinoids.
Alvaro
Torres, Khiron CEO and Director, commented, "Khiron is one of very few
cannabis companies with the cash reserves to continue to aggressively expand
its business operations. Our strong balance sheet and proven operational team
positions us to further take advantage of the tremendous market demand that we
see for CBD consumer products in the LatAm region. The introduction of the
Aceso brand, the first from our joint venture with Dixie Brands, positions us
to build on the brands already wide adoption in the US and translate that
through our establish retail network to consumers in Latin America."
The
launch of Aceso into Colombia continues the Company's strategy to bring
innovative CBD-based cosmeceutical and wellness products to the Latin American
market. In 2018 the Company launched Kuida, a comprehensive line of skincare
products which are now sold across Colombia, are set to launch in the US and
have received approval for commercialization in the UK.
Michael
McMahon, Dixie's General Manager of Latin America, added, "We are excited
to see our joint venture with Khiron starting to yield the opportunities to
introduce our products into the market. This is the tip of the iceberg, and as
we continue to refine our products to meet the regulatory requirements in each
country, we will be expanding into more countries and delving deeper into our
product portfolio."
Neptune Wellness
Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) announced that it has entered into a collaboration
agreement with International Flavors
& Fragrances Inc. (NYSE: IFF) to co-develop hemp-derived CBD products
for the mass retail and health & wellness markets. App Connect Service,
Inc. is also a party to the agreement to provide related branding strategies
and promotional activities. In conjunction with the co-development partnership,
Neptune will issue to warrants(1) to IFF.
Under
this strategic product development partnership, IFF will leverage its
intellectual property (IP) for taste, scent and nutrition to provide essential
oils and product development resources. Neptune will leverage its proprietary
cold ethanol extraction processes and formulation IP to deliver high quality,
full- and broad-spectrum extracts for the development, manufacture and
commercialization of hemp-derived products, infused with essential oils, for
the cosmetics, personal care and home care markets.
The
first products are expected to launch under Neptune's Forest Remedies brand at
U.S. retailers in the first half of calendar 2020. The Initial launch will
include a variety of topical products across the aromatherapy category, a
market estimated at approximately $3 billion annually. Additional category
launches should follow and the total SKU count could ultimately exceed 50 SKUs.
Neptune will be responsible for the marketing and sale of the products. Neptune
will record revenues from product sales and in turn will pay a royalty to each
of IFF and App Connect associated with the sales of co-developed products(2).
"The
agreement represents a significant event in the development of our global
cannabis business, expanding our business model from primarily B2B to include a
robust B2C business platform. IFF has an impressive track record, remarkable
capabilities and global reach. This partnership will accelerate Neptune's
vision and growth strategy to be the leading producer of hemp extracts
ingredients and finished products for the global health & wellness and
Consumer Packaged Goods industries. We are also now better positioned to
leverage our management's experience building brands and relationships with key
North American retailers," stated Michael Cammarata, CEO of Neptune.
"We
are pleased to enter this strategic partnership and drive innovation that
satisfies customers' demands for quality, sustainability and
traceability," said Nicolas Mirzayantz, Divisional CEO, Scent at IFF.
"The hemp-derived CBD products we are developing will target consumer
preference towards natural health & wellness products."
The company also announced their
financial and operating results for the three-month period ended September 30, 2019.
"We have a strong opportunity in the
consumer market, and in recent months I have been focused on developing our B2B
and B2C strategy for the U.S. market. According to most estimates, the U.S.
hemp-derived CBD market is expected to exceed US$20 billion at retail in the
next five years. This market size is roughly three to four times larger than
the expected size of the Canadian cannabis market and represents our largest
opportunity today. The collaboration agreement with IFF and the American Media
partnership will help raise the awareness of our CBD brand, Forest Remedies™.
We expect to introduce our first consumer products at retail locations and
online with rollout commencing in the first half of CY2020," stated
Michael Cammarata, CEO of Neptune.
Aurora Cannabis Inc. (NYSE:
ACB) (TSX:
ACB) announced the
voting results from its Annual General Meeting of Shareholders, held in
Edmonton, Alberta, on November 8, 2019.
The total number of shares represented by
shareholders present in person and by proxy at the meeting was approximately
437.9 million, representing 42.6% of Aurora's issued and outstanding Common
Shares.
All of the matters put forward before
shareholders for consideration and approval as set out in the Company's
Management Information Circular dated September 17, 2019, were approved by the
requisite majority of votes cast at the Meeting. The details of the voting
results for the election of directors are set out below:
|
Nominee
|
# Votes for
|
% Votes for
|
# Votes withheld
|
% Votes withheld
|
|
Ronald Funk
|
109,582,481
|
94.51%
|
6,359,922
|
5.49%
|
|
Shan Atkins
|
111,720,215
|
96.36%
|
4,222,186
|
3.64%
|
|
Norma Beauchamp
|
106,098,650
|
91.51%
|
9,843,752
|
8.49%
|
|
Jason Dyck
|
93,693,691
|
80.82%
|
22,231,335
|
19.18%
|
|
Adam Szweras
|
87,965,457
|
75.88%
|
27,959,570
|
24.12%
|
|
Terry Booth
|
97,756,441
|
84.33%
|
18,168,587
|
15.67%
|
|
Michael Singer
|
93,661,008
|
80.79%
|
22,264,019
|
19.21%
|
|
Steve Dobler
|
89,684,843
|
77.36%
|
26,240,184
|
22.64%
|
The shareholders also approved the: (i)
appointment of KPMG LLP as auditors of the Company for the ensuing year; and
(ii) non-binding advisory resolution on the Company's approach to executive
compensation.
The Company has filed a report of voting
results on all resolutions voted on at the Meeting on www.sedar.com.
Aleafia
Health Inc. (TSX:
ALEF) (OTC:
ALEAF) reported that
Aleafia Farms Inc., its wholly owned subsidiary, produced an inaugural Port
Perry Outdoor Grow harvest yielding approximately 10,300 kg of dried flower.
The yield figure is limited to dried flower, and excludes stems or other parts
of the cannabis plant.
“Today, we can definitively say that
Aleafia Health is among the lowest-cost producers, while realizing close to the
highest revenue per gram sold among our peers as demonstrated in our upcoming
third quarter financial results,” said Aleafia Health CEO Geoffrey Benic.
“Low-cost production will only strengthen our core business model of growing,
producing, selling and exporting high-quality, value-added cannabis health and
wellness products globally.”
2019
OUTDOOR HARVEST HIGHLIGHTS
●
10,300 kg of dried flower harvested
●
1,000 kg per acre yield in Zone 1, which
was planted in June 2019
●
$0.08 cash cost per gram to harvest
(unaudited)
●
$0.10 all-in cash cost per gram to
harvest, including facility capital costs (five-year amortization) (unaudited)
●
Cannabinoid content (THC and CBD per
gram) of harvested flower was strong, at levels near to the cannabinoid content
in identical strains harvested indoor
●
Quality assurance testing to date is
successful, including for microbial content, pesticides and contaminants
“Our inaugural 2019 outdoor harvest was
successful due to the commitment and capabilities of our team. I’d like to
thank our on-site growers who navigated the challenging environment of starting
the cultivation season late into the year and ultimately delivered an excellent
harvest that we are measuring in tons,” said SVP of Production Lucas Escott.
Total yield and 2020 projected yield
figures are approximations. Cash cost per gram to harvest includes all
operating expenses such as labour, supplies, consumables, services and staff
overhead. All-in cash cost per gram to harvest includes all operating expenses,
along with capital costs including irrigation, security infrastructure and the
newly constructed Drying Facility.
As previously announced, Health Canada
amended Aleafia Farms’ license to add Zone 1 to the site on June 7, 2019, with
planting completed by Aleafia Farms within one week. Health Canada amended
Aleafia Farms’ license to add Zone 2 to the site on July 12, 2019, with
planting completed by Aleafia Farms over the last two weeks of July. The six
acre Zone 1, benefiting from an earlier planting date, yielded 1,000 kg per
acre.
Based on the 2019 results, the Company
estimates that it can produce 1,200 kg per acre for a total of 102,000 kg of
dried flower in 2020 at its expanded 3.7 million sq. ft. (86 acre) outdoor
site, at full capacity. The modest increase in the expected yield per acre for
2020 is due a number of factors which should improve the overall outdoor grow
operation, including commencing cultivation several weeks earlier relative to
2019.
GW Pharmaceuticals plc (NASDAQ:
GWPH) announced that
two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex
(nabiximols), have been recommended by the UK’s National Institute for Health
and Care Excellence (NICE) to receive routine reimbursement from NHS England.
This represents the first-time any
plant-derived cannabis-based medicine has been recommended by NICE for use on
the NHS. Cannabidiol oral solution is recommended as an adjunctive therapy for
seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in
conjunction with clobazam, for patients two years of age and older. Nabiximols,
reviewed as part of NICE’s evaluation of cannabis-based medicinal products
(CBMPs), has been considered cost effective for the treatment of spasticity due
to multiple sclerosis.
“This is a momentous occasion for UK
patients and families who have waited for so many years for rigorously tested,
evidenced and regulatory approved cannabis-based medicines to be reimbursed by
the NHS,” said Chris Tovey, GW’s Chief Operating Officer. “This is proof that
cannabis-based medicines can successfully go through extensive randomised
placebo-controlled trials and a rigorous NICE evaluation process to reach
patients. I am hugely proud of the entire GW team for achieving this milestone
in the country where the company was founded and where both of these medicines
were developed and are manufactured.”
Commenting on the NICE recommendation for
cannabidiol oral solution, Dr Rhys Thomas, Consultant Neurologist at the Royal
Victoria Hospital in Newcastle, said: “This is a significant moment for adults
and children with the most difficult to treat epilepsies. NICE’s recommendation
of cannabidiol oral solution follows a period of great anticipation and
enthusiasm for patients and their clinicians. The European Medicines Agency
(EMA) licence and availability through the NHS is welcome as we badly need
additional effective treatments for Dravet and Lennox Gastaut syndromes.”
“We welcome the addition of cannabidiol
oral solution as a new medicine to add to the Dravet syndrome treatment
armamentarium. Dravet syndrome is a devastating condition and having a new
treatment option offers potential new hope to patients and their families
searching for better seizure control,” said Galia Wilson, Chair, Dravet
Syndrome UK. “Many families come to us asking about the potential of
cannabis-based medicines, particularly cannabidiol (CBD), and we are thrilled
that one is now available on the NHS.”
When added to other anti-epileptic therapies,
GW’s cannabidiol oral solution significantly reduced the frequency of seizures
in patients with LGS and Dravet syndrome. The most common adverse reactions
that occurred in patients treated with the medicine were somnolence, decreased
appetite, diarrhoea, pyrexia, fatigue and vomiting. GW’s development programme
represents the only well-controlled clinical evaluation of a cannabinoid
medication for patients with refractory epilepsy.
GW’s cannabidiol oral solution was
approved by the EMA and received marketing authorisation in September 2019
under the trade name EPIDYOLEX as an adjunctive therapy for seizures associated
with LGS or Dravet syndrome, in conjunction with clobazam, for patients two
years of age and older. Following this approval, GW has been working with the
relevant bodies in the UK, Germany, Spain, France and Italy to secure
reimbursement ahead of the anticipated launch of the medicine in these
countries.
The inclusion of nabiximols in NICE
guidelines comes as part of the comprehensive evaluation of the clinical and
cost-effectiveness of CBMPs. Nabiximols has been approved by medicines
regulators in more than 25 countries around the world. Nabiximols was approved
in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in
2010 and is marketed in the UK by GW’s commercial partner, Bayer.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the
Investorideas.com website and
this podcast is not an endorsement to buy products or services or securities.
Investors are reminded all investment involves risk and possible loss of
investment
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com -
News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts
and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech,
water, renewable energy and more. Investor Idea’s original branded content
includes the following podcasts and columns : Crypto
Corner , Play by Play sports and stock
news column, Investor
Ideas Potcasts Cannabis News and Stocks
on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com Global investors
must adhere to regulations of each country. Please read Investorideas.com
privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis
except where permissible by law. Our site does not possess, distribute, or sell
cannabis products.
Follow us on Cannabis Social Media
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment